Table 1:
Patient demographics
| All patients (n=61) | No events (n=11) | Non-HRV events (n=8) | HRV events (n=42) | ||
|---|---|---|---|---|---|
| n | n | n | n | P-value* | |
| Recipient sex | 1.00 | ||||
| Male | 25 (41.0) | 4 (36.4) | 4 (50.0) | 17 (40.5) | |
| Female | 36 (59.0) | 7 (63.6) | 4 (50.0) | 25 (59.5) | |
| Donor sex | 1.00 | ||||
| Male | 29 (48.3) | 6 (54.5) | 3 (37.5) | 20 (48.8) | |
| Female | 31 (51.7) | 5 (45.5) | 5 (62.5) | 21 (51.2) | |
| Race | 0.48 | ||||
| White | 50 (82.0) | 10 (90.9) | 7 (87.5) | 33 (78.6) | |
| Asian | 2 (3.3) | 0 (0.0) | 0 (0.0) | 2 (4.8) | |
| Black or African American | 6 (9.8) | 1 (9.1) | 1 (12.5) | 4 (9.5) | |
| Unknown/not reported | 3 (4.9) | 0 (0.0) | 0 (0.0) | 3 (7.1) | |
| Ethnicity | 0.14 | ||||
| Non-Hispanic/Non-Latino origin | 42 (68.9) | 7 (63.6) | 3 (37.5) | 32 (76.2) | |
| Hispanic/Latino origin | 5 (8.2) | 1 (9.1) | 2 (25.0) | 2 (4.8) | |
| Unknown/not reported | 14 (23.0) | 3 (27.3) | 3 (37.5) | 8 (19.0) | |
| Type of transplant | 0.03 | ||||
| Double lung | 56 (91.8) | 9 (81.8) | 6 (75.0) | 41 (97.6) | |
| Heart-lung | 5 (8.2) | 2 (18.2) | 2 (25.0) | 1 (2.4) | |
| Primary diagnosis | 0.28 | ||||
| Cystic fibrosis | 29 (47.5) | 4 (36.4) | 3 (37.5) | 22 (52.4) | |
| Non-cystic fibrosis | 32 (52.5) | 7 (63.6) | 5 (62.5) | 20 (47.6) | |
| Age at transplant | 0.70 | ||||
| Mean age | 12.15 | 11.96 | 11.08 | 12.41 | |
| Induction medication received | 0.55 | ||||
| Yes | 58 (95.1) | 11 (100.0) | 8 (100.0) | 39 (92.9) | |
| No | 3 (4.9) | 0 (0.0) | 0 (0.0) | 3 (7.1) | |
| Induction medication | 0.48 | ||||
| Basiliximab | 32 (52.5) | 7 (63.6) | 3 (37.5) | 22 (52.4) | |
| Daclizumab | 12 (19.7) | 1 (9.1) | 2 (25.0) | 9 (21.4) | |
| rATG | 14 (23.0) | 3 (27.3) | 3 (37.5) | 8 (19.0) | |
| None | 3 (4.9) | 0 (0.0) | 0 (0.0) | 3 (7.1) | |
HRV = human rhinovirus; rATG = rabbit anti-thymocyte globulin
*
P-value indicates association between patients with HRV events and patients with only non-HRV events or no events.